Dynavax Technologies (United States)

Recent papers from Dynavax Technologies (United States)

1. CpG 1018 and alum synergistically enhance systemic and mucosal immunity to an N2 neuraminidase vaccinenpj Viruses · 2026
2. A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonistsVaccine · 2026
3. An H5N1 clade 2.3.4.4b virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteinsNature Communications · 2026
4. Phase 1/2 Trial of an Investigational Herpes Zoster Vaccine with CpG 1018® Adjuvant and Shingrix in Healthy Adults 50 to 69 Years of AgeOpen Forum Infectious Diseases · 2026
5. A multicountry study to establish rates for pregnancy and neonatal outcomes in low- and middle-income regionsBMC Pregnancy and Childbirth · 2026
6. Compatibility and Stability of a Shigella Polysaccharide—Protein Conjugate Antigen Formulated with Aluminum Salt and CpG 1018® AdjuvantsVaccines · 2025
7. Insights into hepatitis B vaccination decision-making: Exploring vaccine preferences, health disparities, and practice patterns among patients and healthcare providersHuman Vaccines & Immunotherapeutics · 2025
8. A clade 2.3.4.4b H5N1 virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteins2025
9. Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced MelanomaClinical Cancer Research · 2025
10. PfCSP-ferritin nanoparticle malaria vaccine antigen formulated with aluminum-salt and CpG 1018® adjuvants: Preformulation characterization, antigen-adjuvant interactions, and mouse immunogenicity studiesHuman Vaccines & Immunotherapeutics · 2025
11. Enhancing vaccine clinical trials participation among elderly: challenges and strategiesTrials · 2025
12. A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits similar humoral immunity to that of postfusion gB in mice2024
13. Structures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited AntibodiesVaccines · 2024
14. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamstersVaccine · 2024
15. Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformationProceedings of the National Academy of Sciences · 2024
16. Opportunities and challenges with implementing a recycling program for municipal solid waste incineration (MSWI) bottom ash as a construction aggregate: A programmatic reviewJournal of the Air & Waste Management Association · 2024
17. Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation2024
18. A Very Long-acting Exatecan and Its Synergism with DNA Damage Response InhibitorsCancer Research Communications · 2023
19. Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney diseaseVaccine · 2023
20. Demographic diversity of US-based participants in GSK-sponsored interventional clinical trialsClinical Trials · 2023